Anadys Pharmaceuticals

Pioneering the future of hepatitis C treatment with innovative antiviral therapies

General Information
Company Name
Anadys Pharmaceuticals
Founded Year
1992
Location (Offices)
Founders / Decision Makers
Number of Employees
-
Industries
Biotechnology, Health Care
Funding Stage
Private Equity
Social Media

Anadys Pharmaceuticals - Company Profile

Anadys Pharmaceuticals is a biopharmaceutical company that is focused on developing innovative treatments for chronic hepatitis C viral infections. The company's main focus is on advancing ANA598, a direct-acting antiviral specifically designed for hepatitis C treatment. Additionally, Anadys is also involved in resuming the clinical development of ANA773, an oral small-molecule inducer of endogenous interferons that operates via the Toll-like receptor 7 (TLR7). Founded in 1992 and headquartered in San Diego, California, Anadys Pharmaceuticals has been a subsidiary of Hoffmann-La Roche Inc. since November 22, 2011. The company's commitment to innovative antiviral therapies for hepatitis C is reflected in its slogan, "Pioneering the future of hepatitis C treatment with innovative antiviral therapies." Anadys has secured significant funding, with its last investment amounting to $71.30M in a Private Equity Round on 11 August 2005. The investment was made by prominent firms including Venrock, HBM Partners, Coastview Capital, and Lotus BioScience Ventures. Anadys Pharmaceuticals' strong focus on developing cutting-edge treatments for hepatitis C and its history of successful funding partnerships make it a compelling player in the biotechnology and healthcare industries, positioning it as an attractive prospect for potential investors in the biopharmaceutical sector.

Taxonomy: Biopharmaceutical, Hepatitis C treatment, Antiviral therapies, Chronic viral infections, Drug development, Direct-acting antiviral (DAA), Clinical development, Small-molecule inducer, Toll-like receptor 7 (TLR7), San Diego, California, Subsidiary of Hoffmann-La Roche Inc.

Funding Rounds & Investors of Anadys Pharmaceuticals (2)

View All
Funding Stage Amount No. Investors Investors Date
Private Equity Round $71.30M 4 Lotus BioScience Ventures 11 Aug 2005
Seed Round Unknown 1 01 Jan 1993

Latest News of Anadys Pharmaceuticals

View All

No recent news or press coverage available for Anadys Pharmaceuticals.

Similar Companies to Anadys Pharmaceuticals

View All
Idenix Pharmaceuticals - Similar company to Anadys Pharmaceuticals
Idenix Pharmaceuticals Pioneering advancements in antiviral therapies, focused on combating hepatitis and HIV, with a strong presence in the U.S. and Europe.
Replicor Inc. - Similar company to Anadys Pharmaceuticals
Replicor Inc. 292 million people have chronic hepatitis B. We're developing the cure.
Aviron - Similar company to Anadys Pharmaceuticals
Aviron Pioneering advancements in antiviral therapy for chronic Hepatitis C Virus (HCV) infection through robust R&D and strategic collaborations.
Venatorx Pharmaceuticals, Inc. - Similar company to Anadys Pharmaceuticals
Venatorx Pharmaceuticals, Inc. Discovering & developing novel anti-infectives to treat multi-drug resistant bacterial & hard-to-treat viral infections.